Pfizer's nasal spray migraine therapy Zavzpret wins FDA approval
Grandbrothers/iStock Editorial via Getty Images
- The U.S. Food and Drug Administration (FDA) approved Pfizer's (NYSE:PFE) nasal spray Zavzpret (zavegepant) for the acute treatment of migraine with or without aura in adults.
- Pfizer inherited zavegepant from its ~$11.6B acquisition of migraine drugmaker Biohaven.
- Zavzpret is expected to be available in pharmacies in July 2023.
- The company said Zavzpret is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine in adults.
- "The FDA approval of ZAVZPRET marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications," said Angela Hwang, chief commercial officer, president, Global Biopharmaceuticals Business, Pfizer.
- The approval was backed by data from two trials.